EGFR and non-small cell lung carcinoma: Anlotinib reversed acquired resistance to EGFR TKIs via fibroblast growth factor receptor 1 (FGFR1) signaling pathway in T790M‐negative EGFR‐mutant NSCLC in an in vitro trial.9